CGS vs EYE

ASX Healthcare sector comparison — updated 3 Sep 2026 — Healthcare sector

CGS

COGSTATE FPO [CGS]

57MEDIUM

EYE

NOVA EYE FPO [EYE]

58MEDIUM

Score Breakdown

CGS EYE
Technical
61
46
Catalyst
55
54
Sentiment
50
50
Fundamental
99
60
Momentum
64
65
Risk Gate
45
50

Key Metrics

CGS Metric EYE
$523.4MMarket Cap$38.5M
699KAvg Volume (20d)199K
+0.0%Short InterestN/A
$3.23052-Week High$0.205
$1.69052-Week Low$0.100
-0.3%Daily Change+3.8%
$3.070Reference Price$0.135
+22.5%ROE-26.1%
+19.5%Profit Margin-12.4%

Active Signals

CGS Signals

●Beating the Small Ords index — relative strength of 1.21, so it's outpacing the pack
●Trading above the 200-day average — the long-term trend is on your side
●Cash positive / operating cashflow positive
●Moderate P/S ratio (8.6x)
●Moderate revenue growth (+16%)
●Piotroski F-Score strong (8/9, low-confidence approx)
●EPS estimates revised upward (+10pts)
●Near 52-week high (90% of range)

EYE Signals

●Stochastic just turned bullish from a low level — early reversal sign
●Lagging the Small Ords index — relative strength of 0.89, underperforming its peers
●Below the 200-day average — the long-term trend is still working against it
●Critical cash runway (1.2 quarters)
●Low P/S ratio (1.1x)
●Moderate revenue growth (+11%)
●EPS estimates revised upward (+10pts)
●Small-cap ($20-100M)

Ask Scout AI to compare CGS and EYE in depth.

Open Scout AI →

Track both stocks and 2,200+ more — Free

Daily AI-powered screening across every ASX small cap.

Open Screener

Related Comparisons

ATH vs CGS →AHC vs AVE →AHC vs SOM →AVE vs RHT →CUV vs NOX →
CGS Full Analysis → EYE Full Analysis → Healthcare Sector → All Comparisons →
GENERAL INFORMATION ONLY. SmallCapData provides algorithmic screening data and does not constitute personal financial advice, a recommendation, or an offer to buy or sell any security. This content is produced by an algorithm, not a licensed financial adviser. You should consider seeking independent financial advice before making any investment decision. Past performance is not indicative of future results. Trading in small-cap securities carries a high degree of risk, including the risk of total loss of capital. The author may hold positions in mentioned securities. SmallCapData does not hold an Australian Financial Services Licence (AFSL).